Clinical Oncology
Volume 22, Issue 8 , Pages 623-628 , October 2010

The Implementation of Intensity-modulated Radiotherapy in the UK

  • M.V. Williams

      Affiliations

    • Oncology Centre, Addenbrooke’s Hospital, Cambridge University Hospital NHS Trust, Cambridge, UK
    • Corresponding Author InformationAuthor for correspondence: M.V. Williams, Oncology Centre Box 193, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 2QQ, UK. Tel: +44-1223-217020; Fax: +44-1223-274409.
    • ,
  • T. Cooper

      Affiliations

    • National Cancer Action Team, Department of Palliative Care, St Thomas’ Hospital, London, UK
    • ,
  • R. Mackay

      Affiliations

    • North Western Medical Physics, The Christie NHS Foundation Trust, Manchester, UK
    • ,
  • J. Staffurth

      Affiliations

    • Cardiff University, Research Department, Velindre Hospital, Cardiff, UK
    • ,
  • D. Routsis

      Affiliations

    • Oncology Centre, Addenbrooke’s Hospital, Cambridge University Hospital NHS Trust, Cambridge, UK
    • ,
  • N. Burnet

      Affiliations

    • University of Cambridge Department of Oncology, Oncology Centre, Addenbrooke’s Hospital, Cambridge, UK

Received 14 January 2010 ,Accepted 25 June 2010.

References 

  1. Williams MV, Drinkwater KJ. Geographical variation in radiotherapy services across the UK in 2007 and the effect of deprivation. Clin Oncol. 2009;21:431–440
  2. Williams MV, Summer ET, Drinkwater KJ, Barrett A. Radiotherapy dose fractionation, access and waiting times in the countries of the UK in 2005. Clin Oncol. 2007;19:273–286
  3. Department of Health . Radiotherapy: developing a world class service for England. Available at: May 2007;http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_074575last accessed 19 January 2009
  4. Department of Health . Radiotherapy technical development subgroup. Available at: May 2007;http://www.cancer.nhs.uk/documents/nrag_files/technology%20subgroup%20report%20nov06%20-%20fin.pdflast accessed 7 March 2009
  5. Department of Health . Cancer reform strategy. London: Department of Health; 2007;Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_081006
  6. Bentzen SM, Herren G, Cottier B, et al. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: ESTRO QUARTS Project. Radiother Oncol. 2005;75:355–365
  7. The Scottish Government . Cancer in Scotland: radiotherapy activity planning 2011–15. Edinburgh: Scottish Executive; 2005;Available at http://www.scotland.gov.uk/Publications/2006/01/24131719/0
  8. Welsh Assembly Government . Radiotherapy equipment needs and workforce implications 2006–2016. Cancer Services Coordinating Group, Radiotherapy & Chemotherapy Advisory Group. Available at: http://new.wales.gov.uk/about/departments/dhss/publications/health_pub_index/reports/radiotherapyequipmentneeds?lang=enMay 2006;last accessed 3 April 2008
  9. Moller H, Fairley L, Coupland V, et al. The future burden of cancer in England: incidence and numbers of new patients in 2020. Br J Cancer. 2007;96:1484–1488
  10. National Cancer Action Team . NHS cancer programme for England. Radiotherapy – developing a world class service. Available at: http://www.cancer.nhs.uk/radiotherapy/(last accessed 6 January 2010)
  11. Norlund A. Costs of radiotherapy. Acta Oncol. 2003;42:411–415
  12. Ploquin NP, Dunscombe PB. The cost of radiation therapy. Radiother Oncol. 2008;86:217–223
  13. Barton MB, Gebski V, Manderson C, Langlands AO. Radiation therapy: are we getting value for money?. Clin Oncol. 1995;7:287–292
  14. Veldeman L, Madani I, Hulstaert F, De Meerleer G, Mareel M, De Neve W. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol. 2008;9:367–375
  15. Staffurth JN. A review of the clinical evidence for intensity-modulated radiotherapy. Clin Oncol 2010;22:643–657.
  16. Mayles P. Survey of the availability and use of advanced radiotherapy technology in the UK. Clin Oncol 2010;22:636–642.
  17. Van de Werf E, Lievens Y, Verstraete J, Pauwels K, Van den Bogaert W. Time and motion study of radiotherapy delivery: economic burden of increased quality assurance and IMRT. Radiother Oncol. 2009;93:137–140
  18. Williams MV, Hoole ACF, Dean JC, et al. Letter to the Editor: IMRT can be faster to deliver than conformal radiotherapy. Radiother Oncol. 2010;95:257–258
  19. Miles EA, Clark CH, Urbano MT, et al. The impact of introducing intensity modulated radiotherapy into routine clinical practice. Radiother Oncol. 2005;77:241–246
  20. Pearson SD, Ladapo J, Prosser L. Intensity modulated radiation therapy (IMRT) for localized prostate cancer. Available at: http://www.icer-review.org/index.php/imrt.html(last accessed 9 May 2010)
  21. Hummel S, Simpson EL, Hemingway P, Stevenson MD, Rees A. Intensity modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Health Technol Assess (in press).
  22. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8:475–487
  23. National Collaborating Centre for Cancer  on behalf of the National Institute for Health and Clinical Excellence. Prostate cancer: diagnosis and treatment. Available at: http://guidance.nice.org.uk/CG58/Guidance/pdf/English2008;(last accessed 9 May 2010)
  24. Jefferies S, Taylor A, Reznek R and the Radiotherapy Planning Working Party. Results of a national survey of radiotherapy planning and delivery in the UK in 2007. Clin Oncol. 2009;21:204–217
  25. Clark CH, Miles EA, Urbano MT, et al. UK PARSPORT Trial Management Group collaborators. Pre-trial quality assurance processes for an intensity-modulated radiation therapy (IMRT) trial: PARSPORT, a UK multicentre phase III trial comparing conventional radiotherapy and parotid-sparing IMRT for locally advanced head and neck cancer. Br J Radiol. 2009;82:585–594
  26. Sydes MR, Stephens RJ, Moore AR, et al. Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiother Oncol. 2004;72:199–211
  27. Khoo VS, Dearnaley DP. Question of dose-fractionation and technique: ingredients for testing hypo fractionation in prostate cancer – the CHHiP trial. Clin Oncol. 2008;20:12–14
  28. Department of Health. Manual for cancer services . radiotherapy measures. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_1147592008;
  29. MacKay RI, Staffurth J, Poynter A, Routsis D. UK guidelines for the safe delivery of intensity modulated radiotherapy (IMRT). Clin Oncol. 2010;22:707–709
  30. General Medical Council . Consent: patients and doctors making decisions together. Available at: http://www.gmc-uk.org/guidance/ethical_guidance/consent_guidance_index.asp2008;
  31. Maugham TS, et al. Radiotherapy research priorities for the UK. Clin Oncol 2010;22:629–635.

PII: S0936-6555(10)00223-2

doi: 10.1016/j.clon.2010.06.015

Clinical Oncology
Volume 22, Issue 8 , Pages 623-628 , October 2010

Article Tools